Hong Kong Journal of Nephrology
Volume 8, Issue 1 , Pages 5-9, April 2006

Use of MARS in Hepatorenal Syndrome — A Local Perspective

  • Alexander Chiu

      Affiliations

    • Intensive Care Unit, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
    • ,
  • Sheung Tat Fan

      Affiliations

    • Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
    • Intensive Care Unit, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
    • Corresponding Author InformationAddress correspondence and reprint requests to: Professor Sheung Tat Fan, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China. Fax: (+852) 2818-4407

Article Outline

Hepatorenal syndrome is a complication of liver failure with high mortality. All existing treatments, short of liver transplantation, can only be considered as supportive. The molecular adsorbent recirculation system (MARS) is a modified dialysis technique that can remove bilirubin and other albumin-bound toxins, and is now widely used as an artificial liver support system. MARS has been evaluated in many studies, although most have been observational rather than randomized controlled trials. MARS has been demonstrated to be effective in attenuating serum bilirubin, ammonia, creatinine and other hepatotoxin levels in patients, but the biochemical improvement has not been accompanied by an improvement in patient survival. Factors that affect the outcome of patients include timing of implementation, nature of the liver diseases treated, and availability of liver transplantation. MARS preconditioning is another possible indication that aims to improve the postoperative outcome in elective live donor liver transplantation. In the future, randomized controlled trials will be necessary to ascertain the specific role of MARS in the management of liver failure.

Key words:  hepatorenal syndrome , liver failure , MARS , molecular adsorbent recirculation system

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Gines A , Escorsell A , Gines P , Salo J , Jimenez W , Inglada L , et al.   Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites . Gastroenterology . 1993;105:229–236
  2. Hecker R , Sherlock S . Electrolyte and circulatory changes in terminal liver failure . Lancet . 1956;271:1121–1125
  3. Koppel MH , Coburn JW , Mims MM , Goldstein H , Boyle JD , Rubini ME . Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease . N Engl J Med . 1969;280:1367–1371
  4. Arroyo V , Gines P , Gerses AL , Dudley FJ , Gentislini P , Laffi G , et al.   Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis . Hepatology . 1996;23:164–176
  5. Guevara M , Gines P , Fernandez-Esparrach G , Sort P , Salmeron JM , Jimenez W , et al.   Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion . Hepatology . 1998;27:35–41
  6. Gulberg V , Bilzer M , Gerbes AL . Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine . Hepatology . 1999;30:870–875
  7. Uriz J , Gines P , Cardenas A , Sort P , Jimenez W , Salmeron JM , et al.   Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome . J Hepatol . 2000;33:43–48
  8. Guevara M , Gines P , Bandi JC , Gilabert R , Sort P , Jimenez W , et al.   Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems . Hepatology . 1998;28:416–422
  9. Witzke O , Baumann M , Patschan D , Patschan S , Mitchell A , Treichel U , et al.   Which patients benefit from hemodialysis therapy in hepatorenal syndrome? . J Gastroenterol Hepatol . 2004;19:1369–1373
  10. Stange J , Mitzner S , Ramlow W , Gliesche T , Hickstein H , Schmidt R . A new procedure for the removal of protein bound drugs and toxins . ASAIO J . 1993;39:M621–M625
  11. Stange J , Mitzner S . A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patient's blood and a bioartificial liver . Int J Artif Organs . 1996;19:677–691
  12. Evenepoel P , Maes B , Wilmer A , Nevens F , Fevery J , Kuypers D , et al.   Detoxifying capacity and kinetics of the molecular adsorbent recycling system. Contribution of the different inbuilt filters . Blood Purif . 2003;21:244–252
  13. Auth MK , Kim HS , Beste M , Bonzel KE , Baumann U , Ballauff A , et al.   Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children . J Pediatr Gastroenterol Nutr . 2005;40:54–59
  14. Sen S , Davies NA , Mookerjee RP , Cheshire LM , Hodges SJ , Williams R , et al.   Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study . Liver Transpl . 2004;10:1109–1119
  15. Mitzner SR , Stange J , Klammt S , Risler T , Erley CM , Bader BD , et al.   Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial . Liver Transpl . 2000;6:277–286
  16. Stange J , Mitzner SR , Risler T , Erley CM , Lauchart W , Goehl H , et al.   Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support . Artif Organs . 1999;23:319–330
  17. Stange J , Mitzner SR , Klammt S , Freytag J , Peszynski P , Loock J , et al.   Liver support by extracorporeal blood purification: a clinical observation . Liver Transpl . 2000;6:603–613
  18. Heemann U , Treichel U , Loock J , Philipp T , Gerken G , Malago M , et al.   Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study . Hepatology . 2002;36:949–958
  19. Jalan R , Sen S , Steiner C , Kapoor D , Alisa A , Williams R . Extra-corporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis . J Hepatol . 2003;38:24–31
  20. Di Campli C , Santoro MC , Gaspari R , Merra G , Zileri Dal Verme L , Zocco MA , et al.   Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure . Transplant Proc . 2005;37:2547–2550
  21. Lahdenpera A , Koivusalo AM , Vakkuri A , Hockerstedt K , Isoniemi H . Value of albumin dialysis therapy in severe liver insufficiency . Transpl Int . 2005;17:717–723
  22. Koivusalo AM , Vakkuri A , Hockerstedt K , Isoniemi H . Experience of Mars therapy with and without transplantation in 101 patients with liver insufficiency . Transplant Proc . 2005;37:3315–3317
  23. Epstein M . Hepatorenal syndrome. . In:  Epstein M editors. The Kidney in Liver Disease . 4th edition.. Philadelphia: Hanley & Belfus; 1996;p. 75–108
  24. Mitzner SR , Klammt S , Peszynski P , Hickstein H , Korten G , Stange J , et al.   Improvement of multiple organ functions in hepato-renal syndrome during albumin dialysis with the molecular adsorbent recirculating system . Ther Apher . 2001;5:417–422
  25. Palmer RMJ , Ashton DS , Moncada S . Vascular endothelial cells synthesize nitric oxide from L-arginine . Nature . 1988;333:664–666
  26. Martin PY , Gines P , Schrier RW . Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis . N Engl J Med . 1998;339:533–541
  27. Rose C , Felipo V . Limited capacity for ammonia removal by brain in chronic liver failure: potential role of nitric oxide . Metab Brain Dis . 2005;20:275–283
  28. Di Campli C , Zocco MA , Gaspari R , Novi M , Candelli M , Santoliquido A , et al.   The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure . Transplant Proc . 2005;37:2551–2553
  29. Chiu A , Chan LM , Fan ST . MARS treatment for patients with liver failure - the Hong Kong experience . Liver Int . 2006; (in press).
  30. Gonwa TA , Morris CA , Goldstein RM , Husberg BS , Klintmalm GB . Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients . Transplantation . 1991;51:428–430
  31. Gonwa TA , Klintmalm GB , Levy M , Jennings LS , Goldstein RM , Husberg BS . Impact of pretransplant renal function on survival after liver transplantation . Transplantation . 1995;59:361–365
  32. Lerut J , Goffette P , Laterre PF , Donataccio M , Reynaert MS , Otte JB . Sequential treatment of hepatorenal syndrome and posthepatic cirrhosis by intrahepatic portosystemic shunt (TIPSS) and liver transplantation . Hepatogastroenterology . 1995;42:985–987
  33. Nair S , Verma S , Thuluvath PJ . Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation . Hepatology . 2002;35:1179–1185
  34. Choi JY , Bae SH , Yoon SK , Cho SH , Yang JM , Han JY , et al.   Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation-a pilot study . Liver Int . 2005;25:740–745

PII: S1561-5413(09)60223-4

doi:10.1016/S1561-5413(09)60223-4

Hong Kong Journal of Nephrology
Volume 8, Issue 1 , Pages 5-9, April 2006

Article Tools